Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas-Reference-Cited by-同舟云学术

Real-World Evidence of Daratumumab Monotherapy in Relapsed/Refractory Multiple Myeloma Patients and Efficacy on Soft-Tissue Plasmacytomas

Published:2022-08 Issue:8 Volume:22 Page:635-642
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Moreno David F.,Clapés Victoria,Soler Juan Alfons,González-Montes Yolanda,Gironella Mercedes,Motlló Cristina,Granell Miquel,Abella Eugenia,García-Pintos Marta,García-Guiñón Antoni,Cabezudo Elena,Bladé Joan,Rosiñol Laura^ORCID

Funder

Instituto de Salud Carlos III

Janssen Pharmaceuticals

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference41 articles.

1. Bortezomib, lenalidomide, and dexamethasone as induction therapy prior to autologous transplant in multiple myeloma;Rosiñol;Blood,2019

2. Novel drugs for the treatment of multiple myeloma;Blade;Haematologica,2010

3. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors;de Weers;JI,2011

4. Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma;Usmani;Blood,2016

5. Targeting CD38 with daratumumab monotherapy in multiple myeloma;Lokhorst;N Engl J Med,2015

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Daratumumab;Reactions Weekly;2023-06-03

2. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients;Haematologica;2023-02-23

3. Review of daratumumab efficacy in all monoclonal gammopathies and other diseases and our experience with daratumumab, lenalidomide and dexamethasone therapy in 74 patients;Onkologie;2022-10-14

4. Paraskeletal and extramedullary plasmacytomas in multiple myeloma at diagnosis and at first relapse: 50-years of experience from an academic institution;Blood Cancer Journal;2022-09-16

5. Solitary Extramedullary Plasmacytoma of the Larynx and Secondary Laryngeal Involvement in Plasma Cell Myeloma: Single-Centre Retrospective Analysis and Systematic Literature Review;Journal of Clinical Medicine;2022-07-28